StockData

ADC Therapeutics vs Kura Oncology

ADCT and KURA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADCT and KURA compare

Kura Oncology is the larger company, worth 4.0 times as much as ADC Therapeutics ($631M against $160M).

ADC Therapeutics keeps more of each dollar of sales as profit, with a net margin of −95.7% compared with −369% at Kura Oncology.

ADC Therapeutics scores higher on the StockData Score (4 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADCTKURA
Size and price
Market cap$160M$631M
Share price$1.25$7.09
Change, 1 year−69.1%−33.6%
Change, 5 years−94.4%−49.4%
Beta (5Y)2.952.37
Employees188260
StockData Score
Total score4 (better)1
Valuation score1 (better)0
Growth score1 (better)0
Performance score1 (better)0
Health score11
Dividend score00
Valuation
P/S1.9× (better)8.0×
P/B–35.1×
FCF yield−63.0%−14.1% (better)
Growth
Revenue growth (TTM)12.8%–
Profitability
Operating margin−97.7% (better)−394%
Net margin−95.7% (better)−369%
FCF margin−118%−112% (better)
Return on equity–−225%
Financial health
Debt / equity–0.55
Interest coverage−1.6× (better)−227.1×
Current ratio3.053.60 (better)
Altman Z-score−9.16−3.60 (better)
Piotroski F-score6 (better)1
Dividends and buybacks
Buyback yield−26.7%–
Shareholder yield−26.7%0.00% (better)
Ownership
Held by institutions72.9%98.0%
Held by insiders42.8%2.5%
Insider net buying, 12 months−$19.6M−$993K (better)
Short interest, % of float8.8%14.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.